Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
16 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and...
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
13 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human...
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
11 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
26 sept. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08 sept. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
06 sept. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
23 août 2023 10h30 HE
|
Tiziana Life Sciences Ltd.
Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the...
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
23 août 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences informiert über ein Live-Interview mit dem renommierten Wissenschaftler Dr. Howard L. Weiner bei Bloomberg TV, in dem er über die IND-Freigabe der FDA für intranasales Foralumab bei der Alzheimer-Krankheit spricht
18 août 2023 04h30 HE
|
Tiziana Life Sciences Plc
NEW YORK, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) („Tiziana“ oder das „Unternehmen“), ein Biotechnologieunternehmen, das bahnbrechende Immunmodulationstherapien...
Tiziana Life Sciences annonce un entretien en direct sur Bloomberg TV avec le Dr Howard L. Weiner, renommé scientifique, afin de discuter de l'autorisation de la demande de nouveau médicament expérimental auprès de la FDA relative au foralumab intranasal pour la maladie d'Alzheimer
18 août 2023 04h30 HE
|
Tiziana Life Sciences Plc
NEW YORK, 18 août 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq : TLSA) (« Tiziana » ou la « Société »), une société biotechnologique développant des traitements...